Literature DB >> 16141795

Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability.

Danxin Wang1, Andrew D Johnson, Audrey C Papp, Deanna L Kroetz, Wolfgang Sadée.   

Abstract

OBJECTIVES: ABCB1 (multidrug resistance 1 polypeptide, MDR1, Pgp) is a multispecific efflux transporter of drugs and xenobiotics. Among numerous polymorphisms in human ABCB1, the synonymous SNP 3435C > T has been associated with decreased mRNA and protein levels, via unknown mechanisms.
METHODS: To search for cis-acting polymorphism affecting transcription or mRNA processing, we used 3435C > T as a marker single nucleotide polymorphism (SNP), for measuring differences in allelic mRNA expression. Ratios of allelic abundance in genomic DNA and mRNA (after conversion to cDNA) were measured quantitatively with a primer extension assay, in human liver samples.
RESULTS: mRNA expression of the 3435C allele was significantly higher than that of the 3435T allele (3435C/3435T ratios ranging from 1.06-1.61). Cotransfection of equal amounts of ABCB1 expression plasmids containing 3435C or 3435T also revealed higher 3435C mRNA expression. Increasing 3435C/3435T ratios after cessation of transcription indicated that the 3435C > T substitution decreases mRNA stability. 3435C > T is in strong linkage disequilibrium with two other coding SNPs (1236C > T and 2677G > T) forming two abundant haplotypes (ABCB1*1 and ABCB1*13). Transfection of all possible combinations of these three SNPs demonstrated that only 3435T is associated with lower mRNA levels. Calculations of mRNA folding, using Mfold, suggested an effect on mRNA secondary structure.
CONCLUSIONS: the abundant 3435C > T SNP appears to be a main factor in allelic variation of ABCB1 mRNA expression in the liver, by changing mRNA stability.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16141795

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  162 in total

Review 1.  Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.

Authors:  Maarten J Deenen; Annemieke Cats; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2011-05-31

Review 2.  Three decades of low-dose methotrexate in rheumatoid arthritis: can we predict toxicity?

Authors:  Vasco C Romão; Aurea Lima; Miguel Bernardes; Helena Canhão; João Eurico Fonseca
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

3.  Roles of ABCB1 gene polymorphisms and haplotype in susceptibility to breast carcinoma risk and clinical outcomes.

Authors:  Huizhe Wu; Hui Kang; Yong Liu; Weiwei Tong; Duo Liu; Xiuli Yang; Minqiong Lian; Weifan Yao; Haishan Zhao; Desheng Huang; Xianzheng Sha; Enhua Wang; Minjie Wei
Journal:  J Cancer Res Clin Oncol       Date:  2012-04-19       Impact factor: 4.553

Review 4.  Genome-wide approaches to schizophrenia.

Authors:  Jubao Duan; Alan R Sanders; Pablo V Gejman
Journal:  Brain Res Bull       Date:  2010-04-28       Impact factor: 4.077

5.  Effect of ABCB1 haplotypes on the pharmacokinetics and renin-inhibiting effect of aliskiren.

Authors:  Tuija Tapaninen; Pertti J Neuvonen; Mikko Niemi
Journal:  Eur J Clin Pharmacol       Date:  2010-05-23       Impact factor: 2.953

6.  Donor P-gp polymorphisms strongly influence renal function and graft loss in a cohort of renal transplant recipients on cyclosporine therapy in a long-term follow-up.

Authors:  J-B Woillard; J-P Rerolle; N Picard; A Rousseau; A Guillaudeau; E Munteanu; M Essig; M Drouet; Y Le Meur; P Marquet
Journal:  Clin Pharmacol Ther       Date:  2010-05-26       Impact factor: 6.875

Review 7.  Pharmacogenetics as a tool to tailor antiretroviral therapy: A review.

Authors:  Antonio Aceti; Laura Gianserra; Lara Lambiase; Alfredo Pennica; Elisabetta Teti
Journal:  World J Virol       Date:  2015-08-12

8.  CYP2C9 promoter variable number tandem repeat polymorphism regulates mRNA expression in human livers.

Authors:  Danxin Wang; Xiaochun Sun; Yan Gong; Brian E Gawronski; Taimour Y Langaee; Mohamed Hossam A Shahin; Sherief I Khalifa; Julie A Johnson
Journal:  Drug Metab Dispos       Date:  2012-01-30       Impact factor: 3.922

Review 9.  Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.

Authors:  Christine E Staatz; Lucy K Goodman; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2010-03       Impact factor: 6.447

10.  [Pharmacogenomic Biomarkers for the Prediction of Statin Efficacy and Safety].

Authors:  Damiano Baldassarre; Mauro Amato; Beatrice Frigerio; Gualtiero Columbo; Philip F Binkley; Saurabh R Pandey; Adam M Suhy; Katherine Hartmann; Joseph P Kitzmiller
Journal:  G Ital Arterioscler       Date:  2013-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.